Prof. Jonathan Heeney's company receives grant for vaccine development

10th Mar 2022

The Prime Minister has announced that DIOSynVax, a biotech spinout of the University of Cambridge, will receive $42 million (about £32 million) to develop a vaccine candidate that could provide protection against both existing and future variants of SARS-CoV-2 – the virus that causes COVID-19 – as well as other major coronaviruses, including those that cause SARS and MERS.

The investment from the Coalition for Epidemic Preparedness Innovations (CEPI) will support the development of an mRNA vaccine. DIOSynVax, led by Professor Jonathan Heeney, Head of the Laboratory of Viral Zoonotics, University of Cambridge, will design and select the lead antigen through proof-of-concept preclinical studies, and undertake initial clinical development through Phase I/II studies.